MERGER: Sanofi-aventis merger with Genzyme

Sanofi-aventis completed its merger with Genzyme on 4/8/2011 for Sanofi-aventis stock. The SEC filing for this merger can be found through the SEC’s EDGAR web site at: http://www.sec.gov/Archives/edgar/data/1121404/000119312511076085/df4a.htm#rom153596_36a Choose the F-4A filing of 3/24/2011. It is file number 33-172638

This merger is an acquisition merger. It is treated as sell transaction for Genzyme shareholders. The total merger consideration is the value of the cash received plus the value of the Conditional Value Rights. To complete this transaction will require 2 entries in the software. The information below is based on the information available from the F-4 filed with the SEC. Price information is from websites offering historical prices.

The Sell Entry
Go to Transactions > Sell or Accounting > Securities > Sell depending on the version of the software being used.
Here is the information you need to complete the sell transaction.
Date: 4/8/2011
Security: Genzyme (GENZ)
Sale Total: 76.30 x (# of GENZ shares owned)
($74.00 + $2.30) $74.00 = cash $2.30 = value of GCVRZ received per share of Genzyme.

The Buy Entry
Go to Transactions > Buy or Accounting > Securities > Buy depending on the version of the software being used.
Here is the information you need to complete the buy transaction.
Date: 4/8/2011
Security: Sanofi (GCVRZ)
Purchase Total: 2.30 x (# of GCVRZ shares received)
$2.30 = value of GCVRZ received at opening on distribution date.
Enter any commissions and/or fees your broker may have charged.